

Occupational Research Agenda (NORA) and to develop recommendations for implementation of the agenda. Invited participants will form review panels and review the draft NORA in sessions open to the public. A limited amount of time will be reserved to provide members of the public attending the meeting the opportunity to comment on the research priorities and recommendations on implementation. The tentative agenda of the meeting begins with a discussion of the development of the list of research priorities included in the draft NORA. Participants will break into smaller groups to review the draft and make recommendations on implementation of the NORA. In the afternoon session, each Work Group will present a summary of their comments. A limited amount of time will be reserved following the Work Group presentations for public comment and discussion. Three to five minute presentations on the draft NORA may be made during the public session. The exact time limit of the presentations will depend upon the number of people wishing to present. The draft NORA will be available for distribution on February 23, 1996. NIOSH encourages the public to provide comments on research priorities through March 6, 1996. The final NORA will be released on April 29, 1996. To attend this meeting, receive a copy of the draft NORA, or receive additional information on NORA, please contact Mr. Chris Olenec as indicated below. On-site registration will be available; however, to assist in planning for the meeting, advance registration is requested.

CONTACT PERSON FOR ADDITIONAL INFORMATION: Mr. Chris Olenec, NIOSH, CDC, 200 Independence Avenue, Room 317B, Washington, DC 20201, telephone 202/205-2640, FAX 202/260-1898. When possible, please FAX requests for copies of the draft research agenda.

WRITTEN COMMENTS TO: Ms. Diane Manning, NIOSH, CDC, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.

Dated: February 20, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-4337 Filed 2-26-96; 8:45 am]

BILLING CODE 4163-19-M

Food and Drug Administration

Advisory Committee Meeting; Postponement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Food Advisory Committee scheduled for February 28 and 29, 1996. The meeting was announced by a notice in the Federal Register of February 8, 1996 (61 FR 4783). The Food Advisory Committee will meet in the near future and announce its notice of meeting in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Lynn A. Larsen, Center for Food Safety and Applied Nutrition (HFS-5), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4727.

Dated: February 21, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96-4348 Filed 2-26-96; 8:45 am]

BILLING CODE 4160-01-F

Advisory Committee Meetings; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing amendments to the notice of meetings of the Antiviral Drugs Advisory Committee, the Endocrinologic and Metabolic Drugs Advisory Committee, and the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Antiviral Drugs Advisory Committee. These meetings were announced in the Federal Register of January 31, 1996 (61 FR 3427). The amendments reflect a change in the location of the Antiviral Drugs Advisory Committee meeting on the third day. The 3-day meeting will now be held at the same location. In addition, the location has been changed for the other meetings. There are no other changes. The amendments will be announced at the beginning of the open portion of the meetings.

FOR FURTHER INFORMATION CONTACT:

For the Antiviral Drugs Advisory Committee Meeting: Ermona McGoodwin, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

For both the Endocrinologic and Metabolic Drugs Advisory Committee Meeting and the Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Antiviral Drugs Advisory Committee: Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 31, 1996 (61 FR 3427), FDA announced: (1) A meeting of the Antiviral Drugs Advisory Committee would be held on February 28 and 29, and March 1, 1996; (2) a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on February 29, 1996; and (3) a joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Antiviral Drugs Advisory Committee would be held on March 1, 1996. On page 3428, beginning in the second column, the "Date, time, and place" portion of the Antiviral Drugs Advisory Committee is amended to read as follows:

Date, time, and place. February 28 and 29, and March 1, 1996, 8:30 a.m., Holiday Inn—Gaithersburg, Grand Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

On page 3429, in the first column, the "Date, time, and place" portion of the Endocrinologic and Metabolic Drugs Advisory Committee is amended to read as follows:

Date, time, and place. February 29, 1996, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

On the same page, in the second column, the "Date, time, and place" portion of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Antiviral Drugs Advisory Committee is amended to read as follows:

Date, time, and place. March 1, 1996, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Dated: February 22, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96-4575 Filed 2-23-96; 4:12 pm]

BILLING CODE 4160-01-F